Novo Nordisk has introduced a subscription program for its Wegovy obesity drugs, offering patients three-, six-, or 12-month plans with lower, predictable monthly prices. The program covers both Wegovy injections and the higher doses of the newly launched pill, with longer subscriptions providing greater savings—up to $1,200 annually on injections and $600 on pills. Available through several telehealth partners, the initiative aims to help patients maintain consistent treatment despite pricing challenges and upcoming competition from Eli Lilly's oral GLP-1 drug. Patients can opt out anytime, and the program may expand to NovoCare's pharmacy platform in the future.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
